NCT05592262 is a Phase 1 clinical trial of SHR2554 in Malignant Tumor, sponsored by Jiangsu HengRui Medicine Co., Ltd..

Who is sponsoring NCT05592262?

NCT05592262 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT05592262?

Interventions in NCT05592262: SHR2554, SHR2554.

What condition does NCT05592262 study?

NCT05592262 studies Malignant Tumor.

Is NCT05592262 still recruiting?

NCT05592262 is currently completed. Last updated 19 December 2022.

Last reviewed 2022-12-19 · How we verify

NCT05592262

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects

Completed Phase 1 Last updated 19 December 2022

What this trial tests

Phase 1 trial testing SHR2554 in Malignant Tumor in 20 participants. Completed in 14 December 2022.

Timeline

15 November 2022

Primary endpoint
14 December 2022

14 December 2022

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	15 November 2022
Primary completion	14 December 2022
Estimated completion	14 December 2022
Sites	1 location across China

Drugs / interventions tested

SHR2554 — full drug profile →
SHR2554 — full drug profile →

Conditions studied

Malignant Tumor — all drugs for Malignant Tumor →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 45, any sex, with Malignant Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to assess the effect of food on the pharmacokinetics, and safety of SHR2554 Tablets in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of SHR2554

Trials testing the same drug.

NCT07125950 — SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT05559008 — A Umbrella Study in R/R PTCL Guided by Molecular Subtypes · Phase 1, PHASE2 · unknown
NCT04355858 — Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer · Phase 2 · unknown
NCT04335266 — A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects · Phase 1 · completed

Other recruiting trials for Malignant Tumor

Currently open trials in the same condition.

NCT07193329 — Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life · recruiting
NCT06618274 — Effectiveness of Central Oncology Navigation and the Use of an ORN · NA · recruiting
NCT06674889 — Rehabilitation Outcomes Study · NA · recruiting
NCT05862259 — A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies · recruiting
NCT05596344 — Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05592262 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 19 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05592262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing